Actively Recruiting
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Led by British Columbia Cancer Agency · Updated on 2026-01-16
200
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
T
Terry Fox Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.
CONDITIONS
Official Title
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced pancreatic ductal adenocarcinoma (PDAC)
- Medically fit and planned to undergo laparoscopic procedure as part of standard care
- Able to give informed consent for study-related procedures during laparoscopy
- Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer
- Medically fit to undergo surgical resection of primary lesion(s) for resectable and borderline resectable cohorts
- Planned for adjuvant or first-line therapy with FOLFIRINOX or gemcitabine-based regimen, alone or with investigational agents
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function as defined by specified laboratory results within 28 days prior to enrollment
- Life expectancy greater than 90 days
- Measurable disease by RECIST 1.1; for resectable and borderline cohorts, measurable disease must be present before surgery
You will not qualify if you...
- Presence of distant or lymph node metastases
- Currently receiving adjuvant or systemic anti-cancer therapy, except pre-operative therapy
- Not fit for chemotherapy
- Presence of brain metastases
- Positive pregnancy test
- Unable to comply with study assessments and procedures
- Judged unfit to proceed with the protocol by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BC Cancer
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
Research Team
D
Daniel J Renouf, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here